193 related articles for article (PubMed ID: 26279147)
21. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.
Fernandes R; Mazzarello S; Joy AA; Pond GR; Hilton J; Ibrahim MFK; Canil C; Ong M; Stober C; Vandermeer L; Hutton B; da Costa M; Damaraju S; Clemons M
Support Care Cancer; 2018 Sep; 26(9):3073-3081. PubMed ID: 29564623
[TBL] [Abstract][Full Text] [Related]
22. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Pabst L; Velten M; Fischbach C; Kalish M; Pflumio C; Pivot X; Petit T
Breast J; 2020 Dec; 26(12):2376-2382. PubMed ID: 33307596
[TBL] [Abstract][Full Text] [Related]
23. Effects of taxane-induced peripheral neuropathy on hand dexterity impairment: evaluation of quantitative and subjective assessments.
Manfuku M; Inoue J; Yamanaka N; Kanamori H; Sumiyoshi K; Osumi M
Support Care Cancer; 2024 Apr; 32(5):304. PubMed ID: 38652168
[TBL] [Abstract][Full Text] [Related]
24. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
[TBL] [Abstract][Full Text] [Related]
25. Defining risks of taxane neuropathy: insights from randomized clinical trials.
Kudlowitz D; Muggia F
Clin Cancer Res; 2013 Sep; 19(17):4570-7. PubMed ID: 23817688
[TBL] [Abstract][Full Text] [Related]
26. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment.
Timmins HC; Li T; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB
Support Care Cancer; 2020 Sep; 28(9):4459-4466. PubMed ID: 31925531
[TBL] [Abstract][Full Text] [Related]
27. Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy.
Pan Y; Kao MS
Int J Gynecol Cancer; 2007; 17(2):394-7. PubMed ID: 17362318
[TBL] [Abstract][Full Text] [Related]
28. Genetic determinants of taxane-induced peripheral neuropathy.
Mladosievicova B; Jablonicka MN; Tatayova L; Bernadic M
Bratisl Lek Listy; 2024; 125(4):207-210. PubMed ID: 38526855
[TBL] [Abstract][Full Text] [Related]
29. [Expert consensus on standardized management of taxane-related peripheral neuropathy].
Taxane-related Peripheral Neuropathy Standardized Management Group
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):170-179. PubMed ID: 32252195
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Bandla A; Tan S; Kumarakulasinghe NB; Huang Y; Ang S; Magarajah G; Hairom Z; Lim JSJ; Wong A; Chan G; Ngoi N; Ang E; Lee YM; Chan A; Lee SC; Thakor N; Wilder-Smith E; Sundar R
Support Care Cancer; 2020 Aug; 28(8):3691-3699. PubMed ID: 31811482
[TBL] [Abstract][Full Text] [Related]
31. What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer.
Bridges CM; Smith EM
Support Care Cancer; 2014 Sep; 22(9):2581-92. PubMed ID: 24952242
[TBL] [Abstract][Full Text] [Related]
32. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).
Williams LA; Garcia-Gonzalez A; Mendoza TR; Haq S; Cleeland CS
Support Care Cancer; 2019 Mar; 27(3):1021-1028. PubMed ID: 30094731
[TBL] [Abstract][Full Text] [Related]
33. [Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy].
Koyanagi M; Imai S; Nakagawa T; Matsubara K
Nihon Yakurigaku Zasshi; 2019; 154(5):241-244. PubMed ID: 31735751
[TBL] [Abstract][Full Text] [Related]
34. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
Osmani K; Vignes S; Aissi M; Wade F; Milani P; Lévy BI; Kubis N
J Neurol; 2012 Sep; 259(9):1936-43. PubMed ID: 22349867
[TBL] [Abstract][Full Text] [Related]
35. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer.
Kishida Y; Tsushima T; Endo M; Hamauchi S; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
Am J Clin Oncol; 2018 Jan; 41(1):41-45. PubMed ID: 26422718
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
37. Effect of a Complementary/Integrative Medicine Treatment Program on Taxane-Induced Peripheral Neuropathy: A Brief Report.
Ben-Arye E; River Y; Keshet Y; Lavie O; Israeli P; Samuels N
Int J Gynecol Cancer; 2018 Jun; 28(5):1045-1049. PubMed ID: 29561303
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Sucheston-Campbell LE; Clay-Gilmour AI; Barlow WE; Budd GT; Stram DO; Haiman CA; Sheng X; Yan L; Zirpoli G; Yao S; Jiang C; Owzar K; Hershman D; Albain KS; Hayes DF; Moore HC; Hobday TJ; Stewart JA; Rizvi A; Isaacs C; Salim M; Gralow JR; Hortobagyi GN; Livingston RB; Kroetz DL; Ambrosone CB
Pharmacogenet Genomics; 2018 Feb; 28(2):49-55. PubMed ID: 29278617
[TBL] [Abstract][Full Text] [Related]
39. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?
Noronha V; Patil V; Joshi A; Muddu V; Bhattacharjee A; Juvekar S; Arya S; Chaturvedi P; Chaukar D; Pai PS; Dcruz AK; Prabhash K
Indian J Cancer; 2015; 52(1):70-3. PubMed ID: 26837979
[TBL] [Abstract][Full Text] [Related]
40. Peripheral sensory neuropathy in type 2 diabetes patients: A case control study in Accra, Ghana.
Yeboah K; Puplampu P; Boima V; Antwi DA; Gyan B; Amoah AGB
J Clin Transl Endocrinol; 2016 Sep; 5():26-31. PubMed ID: 29067231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
